{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:51:55Z","timestamp":1768258315163,"version":"3.49.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T00:00:00Z","timestamp":1664668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"2020 Shanxi Province Emerging Industry Leadership Project and Youth Fund of the Second Hospital of Shanxi Medical University","award":["no. 201902-6"],"award-info":[{"award-number":["no. 201902-6"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular lesions, immunological alterations and tissue fibrosis. There is some evidence of an imbalance between T-cell subsets in this disease. Interleukin (IL)-2 is a cytokine that can regulate the activity of immune cells and there is evidence that low-dose IL-2 therapy can be used to treat immune diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the changes of peripheral lymphocyte subsets, especially T helper (Th)17 and regulatory T (Treg) cells and the effects of low-dose IL-2 therapy in patients with SSc.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In total, 66 patients with SSc and 49 sex- and age-matched healthy controls (HCs), were enrolled. The absolute numbers of peripheral lymphocyte subsets in these individuals were determined by flow cytometry. The 66 patients, were divided into 2 groups: 23 (the IL-2 group) were treated with low-dose (5.0 \u00d7 105 IU) IL-2 by subcutaneous injection daily for 5 days combined with conventional therapy, while the remaining 23 patients received conventional therapy only.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with HCs, the absolute numbers of peripheral T, CD4+ T, CD8+ T, natural killer and Treg cells were significantly lower in patients with SSc, with the most dramatic difference seen in both the absolute number and percentage of Treg cells in these patients, including new (previously untreated) cases, resulting in an imbalance (elevated ratio) between Th17 and Treg cells. At Week 24 after commencement of IL-2 treatment, Treg cells were markedly increased and tended to restore the balance of Th17 to Treg cells compared with baseline. Erythrocyte sedimentation rate, C-reactive protein, modified Rodnan Skin Score and visual analogue scale score were significantly decreased in both the IL-2 and non-IL-2 groups, indicating disease improvement. Notably, compared with those in the non-IL-2 group, patients treated with IL-2 had greater improvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study showed that the absolute numbers of peripheral Treg cells together with total T, CD4+ T, CD8+ T and NK is significantly decreased, leading to an imbalance of Th17 to Treg cells in patients with SSc, and that low-dose IL-2 treatment could restore the balance of the two immune cells and reduce disease activity without obvious adverse effects.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ced.15345","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:22:55Z","timestamp":1659140575000},"page":"2188-2195","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Absolute decrease in regulatory T cells and low-dose interleukin-2 therapy: restoring and expanding regulatory T cells to treat systemic sclerosis: a 24-week study"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9703-3244","authenticated-orcid":false,"given":"Zhen","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Rheumatology Shanxi Medical University Second Affiliated Hospital Taiyuan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Shanxi Medical University Second Affiliated Hospital Taiyuan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Shanxi Medical University Second Affiliated Hospital Taiyuan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuying","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Shanxi Medical University Second Affiliated Hospital Taiyuan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglan","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Shanxi Medical University Second Affiliated Hospital Taiyuan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital Harvard Medical School Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Shanxi Medical University Second Affiliated Hospital Taiyuan China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"2023010808134211600_ced15345-bib-0001","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-017-8608-5","article-title":"Could lymphocyte profiling be useful to diagnose systemic autoimmune diseases?","volume":"53","author":"Carvajal Alegria","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023010808134211600_ced15345-bib-0002","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3389\/fimmu.2018.02356","article-title":"Regulatory T cells in systemic sclerosis","volume":"9","author":"Frantz","year":"2018","journal-title":"Front Immunol"},{"key":"2023010808134211600_ced15345-bib-0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13075-018-1569-0","article-title":"Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression","volume":"20","author":"Bosello","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2023010808134211600_ced15345-bib-0004","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/jir.2018.0016","article-title":"Interleukin-2 deficiency associated with renal impairment in systemic lupus erythematosus","volume":"39","author":"Shao","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"2023010808134211600_ced15345-bib-0005","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","article-title":"Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sj\u00f6gren's syndrome","volume":"77","author":"Miao","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023010808134211600_ced15345-bib-0006","article-title":"Circulating regulatory T cells were absolutely decreased in dermatomyositis\/polymyositis patients and restored by low-dose IL-2","volume":"80","author":"Zhang","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023010808134211600_ced15345-bib-0007","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). subcommittee for scleroderma criteria of the American Rheumatism association diagnostic and therapeutic criteria committee","volume":"23","author":"Anonymous","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2023010808134211600_ced15345-bib-0008","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023010808134211600_ced15345-bib-0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2023010808134211600_ced15345-bib-0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biopha.2018.09.037","article-title":"Imbalance between T helper 17 and regulatory T cell subsets plays a significant role in the pathogenesis of systemic sclerosis","volume":"108","author":"Mo","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"2023010808134211600_ced15345-bib-0011","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.3760\/cma.j.issn.0366-6999.20141395","article-title":"Correlation of Th17 cells and CD4+CD25+ regulatory T cells with clinical parameters in patients with systemic sclerosis","volume":"127","author":"Jiang","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"2023010808134211600_ced15345-bib-0012","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/14397595.2014.899736","article-title":"Decreased expression of Runx1 and lowered proportion of Foxp3+CD25+CD4+ regulatory T cells in systemic sclerosis","volume":"25","author":"Kataoka","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2023010808134211600_ced15345-bib-0013","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/bloodadvances.2017011072","article-title":"Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients","volume":"2","author":"Arruda","year":"2018","journal-title":"Blood Adv"},{"key":"2023010808134211600_ced15345-bib-0014","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5493\/wjem.v7.i3.84","article-title":"Treg\/Th17 cell balance and phytohaemagglutinin activation of T lymphocytes in peripheral blood of systemic sclerosis patients","volume":"7","author":"Krasimirova","year":"2017","journal-title":"World J Exp Med"},{"key":"2023010808134211600_ced15345-bib-0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cytogfr.2015.12.002","article-title":"New insights into CD4+ T cell abnormalities in systemic sclerosis","volume":"28","author":"Liu","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"2023010808134211600_ced15345-bib-0016","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-2140-3","article-title":"Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort","volume":"22","author":"Panopoulos","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023010808134211600_ced15345-bib-0017","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1074-7613(02)00367-9","article-title":"CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2","volume":"17","author":"Malek","year":"2002","journal-title":"Immunity"},{"key":"2023010808134211600_ced15345-bib-0018","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"2023010808134211600_ced15345-bib-0019","first-page":"716","article-title":"Systemic sclerosis \u2013 the dermatological perspective","volume":"17","author":"Sticherling","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"2023010808134211600_ced15345-bib-0020","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1084\/jem.20030917","article-title":"Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis","volume":"198","author":"Kitani","year":"2003","journal-title":"J Exp Med"},{"key":"2023010808134211600_ced15345-bib-0021","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1161\/CIRCULATIONAHA.108.832782","article-title":"Regulatory T cells ameliorate angiotensin II-induced cardiac damage","volume":"119","author":"Kvakan","year":"2009","journal-title":"Circulation"},{"key":"2023010808134211600_ced15345-bib-0022","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/hep.30061","article-title":"Interleukin 2 promotes hepatic regulatory T cell responses and protects from biliary fibrosis in murine sclerosing cholangitis","volume":"68","author":"Taylor","year":"2018","journal-title":"Hepatology"},{"key":"2023010808134211600_ced15345-bib-0023","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molimm.2019.07.002","article-title":"Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg\/Teff cells and reducing spleen germinal center formation","volume":"114","author":"Wang","year":"2019","journal-title":"Mol Immunol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ced.15345","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ced.15345","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/47\/12\/2188\/48531212\/ced2188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/47\/12\/2188\/48531212\/ced2188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:36:20Z","timestamp":1727678180000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/47\/12\/2188\/6966192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,1]]},"published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1111\/ced.15345","relation":{},"ISSN":["1365-2230","0307-6938"],"issn-type":[{"value":"1365-2230","type":"electronic"},{"value":"0307-6938","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"2022-07-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}